Oruka Therapeutics, Inc.
ORKA evidence brief
What we can confirm
- BioSniper Score:
- 4.4 / 10
- Market Cap:
- $6.06B
- Lead Asset:
- gencaro
What it means
What to watch
Prepared research question
What matters most for ORKA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ORKA
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing novel monoclonal antibodies targeting IL-23p19, IL-17A/F, and TL1A for inflammatory and immunology indications, with a lead program in psoriasis and a co-lead program in hidradenitis suppurativa and psoriatic arthritis.
Key risk: No product revenue
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$6.06B
Cash Runway
—
Lead Asset
gencaro
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 7 clinical trials for Oruka Therapeutics, Inc..
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing novel monoclonal antibodies targeting IL-23p19, IL-17A/F, and TL1A for inflammatory and immunology indications, with a lead program in psoriasis and a co-lead program in hidradenitis suppurativa and psoriatic arthritis.
- Oruka Therapeutics is a clinical-stage biopharmaceutical company focused on novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology (I&I) indications [sec · filed 2026-08-21].
- Lead program ORKA-001 targets IL-23p19 for psoriasis; co-lead ORKA-002 targets IL-17A/F for psoriasis, hidradenitis suppurativa, and psoriatic arthritis [sec_mda · as of 2026-08-10].
- As of June 30, 2026, the company reported cash, cash equivalents, and marketable securities of $1.1 billion, with an accumulated deficit of $262.2 million [sec_mda · as of 2026-08-10].
- The company expects cash runway to fund operations through BLA for ORKA-001, with post-offering cash, cash equivalents, and marketable securities sufficient for that purpose [news · published 2026-05-13].
- ORKA-004, a novel extended half-life antibody targeting TL1A, is anticipated to enter clinical development in Q4 2026, with Phase 2 combination trials planned for 2027 [sec_mda · as of 2026-08-10].
What works
- Strong cash position of $1.1 billion as of June 30, 2026, providing extended runway through key clinical milestones and BLA submission [sec_mda · as of 2026-08-10].
- Lead program ORKA-001 demonstrated a 63.5% PASI 100 rate at 16 weeks in the EVERLAST-A trial, indicating high efficacy with a favorable tolerability profile [news · published 2026-05-13].
- Pipeline includes multiple programs targeting validated I&I mechanisms (IL-23p19, IL-17A/F, TL1A) with half-life extension technology aimed at reducing dosing frequency [sec_mda · as of 2026-08-10].
What to weigh
- The company has incurred significant losses and negative cash flows since inception, with an accumulated deficit of $262.2 million as of June 30, 2026 [sec_mda · as of 2026-08-10].
- Net loss of $41.2 million for the three months ended June 30, 2026, and net cash used for operating activities of $56.7 million during the six months ended June 30, 2026 [sec_mda · as of 2026-08-10].
- All programs are in clinical or preclinical stages; no product revenue has been generated, and profitability depends entirely on successful development and commercialization [sec_mda · as of 2026-08-10].
- Forward-looking statements involve numerous risks and uncertainties that could cause actual results to differ materially from projections [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
Lead program ORKA-001 targets IL-23p19 for psoriasis
“Our lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 ("IL-23p19") for the treatment of PsO.”
SEC MD&A · August 10, 2026
Co-lead program ORKA-002 targets IL-17A/F for multiple indications
“Our co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F ("IL-17A/F") for the treatment of PsO, hidradenitis suppurativa ("HS"), psoriatic arthritis ("PsA"), and other conditions.”
SEC MD&A · August 10, 2026
Cash position of $1.1 billion as of June 30, 2026
“We had cash, cash equivalents, and marketable securities of $1.1 billion as of June 30, 2026.”
SEC MD&A · August 10, 2026
Accumulated deficit of $262.2 million as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $262.2 million.”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2024-12-19 · Phase 1 start for ORKA-001 — First-in-human, double-blind, placebo-controlled, single dose escalation study to evaluate safety, tolerability, and pharmacokinetics of ORKA-001 in healthy participants.
- 2025-05-19 · Phase 1 start for ORKA-002 — First-in-human, double-blind, placebo-controlled, single dose escalation study to evaluate safety, tolerability, and pharmacokinetics of ORKA-002 in healthy participants.
- 2025-07-18 · Phase 2 start for ORKA-001 (psoriasis) — Multicenter, randomized, double-blinded, placebo-controlled study to evaluate efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in participants with moderate-to-severe plaque psoriasis.
- 2025-12-03 · Phase 2 start for ORKA-002 (psoriasis) — Multicenter, randomized, double-blinded, placebo-controlled study to evaluate efficacy, safety, tolerability, and pharmacokinetics of ORKA-002 in participants with moderate-to-severe plaque psoriasis.
Risks & what to watch (4)›
Key risks
- No product revenue — Company has no product revenue and profitability depends entirely on successful development and commercialization of pipeline programs [sec_mda · as of 2026-08-10].
- Significant accumulated deficit — Accumulated deficit of $262.2 million as of June 30, 2026, with ongoing net losses and cash burn [sec_mda · as of 2026-08-10].
- Clinical trial execution risk — All programs are in clinical or preclinical stages; delays or failures in trials (e.g., ORKA-001, ORKA-002) could materially impact timelines and financial position [sec_mda · as of 2026-08-10].
- Forward-looking uncertainties — Numerous risks and uncertainties could cause actual results to differ materially from forward-looking statements [sec_mda · as of 2026-08-10].
What to watch
- Longer-term data from ORKA-001 EVERLAST-A trial expected in 2H 2026 [news · published 2026-05-13].
- Initiation of ORKA-004 clinical development anticipated in Q4 2026 [sec_mda · as of 2026-08-10].
- ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis data expected in 2027 [news · published 2026-05-13].
- Phase 2 combination trials for ORKA-004 with ORKA-001 and ORKA-002 planned to begin in 2027 [sec_mda · as of 2026-08-10].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Oruka Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Oruka Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.02
No tracked pipeline phase
1 candidate
No upcoming catalysts tracked
0 buys · 58 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
184
Total value held
$2.57B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 7,431,403 | $364.5M |
| venrock adviser, llc | 4,148,428 | $203.5M |
| fairmount funds management llc | 3,705,262 | $181.7M |
| blackrock, inc. | 3,527,087 | $173.0M |
| viking global investors lp | 2,666,690 | $130.8M |
| paradigm biocapital advisors lp | 2,320,316 | $113.8M |
| rtw investments, lp | 2,058,148 | $101.0M |
| deep track capital, lp | 2,034,203 | $99.8M |
| vanguard capital management llc | 1,859,631 | $91.2M |
| avidity partners management lp | 1,520,848 | $89.3M |
Showing top 10 of 184 institutional holders of Oruka Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 17.9%
- Days to cover
- 3.5
- Shares short
- 6,992,310
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ORKA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Oruka Therapeutics, Inc.?
Oruka Therapeutics is a clinical-stage biopharmaceutical company developing novel monoclonal antibodies targeting IL-23p19, IL-17A/F, and TL1A for inflammatory and immunology indications, with a lead program in psoriasis and a co-lead program in hidradenitis suppurativa and psoriatic arthritis.
Who is the CEO of Oruka Therapeutics, Inc.?
Dr. Lawrence Otto Klein Ph.D. is the chief executive officer of Oruka Therapeutics, Inc. (ORKA).
Where is Oruka Therapeutics, Inc. headquartered?
Oruka Therapeutics, Inc. (ORKA) is headquartered in Menlo Park, CA, United States.
What therapeutic areas does Oruka Therapeutics, Inc. focus on?
Oruka Therapeutics, Inc. develops therapies across Immunology, Cardiovascular, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.